Literature DB >> 25624071

Racial and Ethnic Differences in Mortality and Cardiovascular Events Among Patients With End-Stage Renal Disease Due to Lupus Nephritis.

Jose A Gómez-Puerta1, Candace H Feldman1, Graciela S Alarcón2, Hongshu Guan1, Wolfgang C Winkelmayer3, Karen H Costenbader1.   

Abstract

OBJECTIVE: To identify racial and ethnic differences in mortality and cardiovascular (CV) risk among patients with end-stage renal disease (ESRD) due to lupus nephritis (LN).
METHODS: Within the US ESRD registry (1995-2008), we identified individuals ages >17 years with incident ESRD due to systemic lupus erythematosus. We ascertained demographics, clinical factors, and deaths from registry patient files and CV events (myocardial infarction, heart failure, and hemorrhagic and ischemic strokes) from inpatient Medicare claims. We calculated incidence rates (95% confidence intervals [95% CIs]) per 1,000 person-years for study events, stratified by race and ethnicity. We compared probabilities of the events among racial and ethnic groups using cumulative incidence function curves and multivariable-adjusted subdistribution proportional hazard ratios (HRsd), taking into account the competing events of kidney transplantation and death (for nonfatal CV events).
RESULTS: Of 12,533 patients with LN-associated ESRD, the mean ± SD age was 40.7 ± 14.9 years, 82% were women, and 49% were African American. The overall mortality rate was 98.1/1,000 person-years (95% CI 95.3-100.9). In multivariable models, Asian and Hispanic LN-associated ESRD patients had lower mortality than whites (HRsd 0.70 [95% CI 0.58-0.84] and 0.79 [95% CI 0.71-0.88], respectively), whereas African Americans had higher mortality (HRsd 1.27 [95% CI 1.18-1.36]). African American patients >40 years old had higher mortality than their white counterparts (HRsd 1.67 [95% CI 1.44-1.93]). African Americans were more likely to be admitted for heart failure or hemorrhagic stroke.
CONCLUSION: Among patients with LN-associated ESRD, Asians and Hispanics experienced lower mortality and CV event risks than whites, and African Americans had higher mortality and CV event risks than whites.
© 2015, American College of Rheumatology.

Entities:  

Mesh:

Year:  2015        PMID: 25624071      PMCID: PMC4515402          DOI: 10.1002/acr.22562

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  33 in total

1.  Racial disparities in age at time of cardiovascular events and cardiovascular-related death in patients with systemic lupus erythematosus.

Authors:  Lisabeth V Scalzi; Christopher S Hollenbeak; Li Wang
Journal:  Arthritis Rheum       Date:  2010-09

2.  Discrepancy between Medical Evidence Form 2728 and renal biopsy for glomerular diseases.

Authors:  J Bradley Layton; Susan L Hogan; Caroline E Jennette; Barbara Kenderes; Jenna Krisher; J Charles Jennette; William M McClellan
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-05       Impact factor: 8.237

3.  Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis.

Authors:  H M Bastian; J M Roseman; G McGwin; G S Alarcón; A W Friedman; B J Fessler; B A Baethge; J D Reveille
Journal:  Lupus       Date:  2002       Impact factor: 2.911

Review 4.  The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis.

Authors:  Allan J Collins; Robert N Foley; David T Gilbertson; Shu-Chen Chen
Journal:  Clin J Am Soc Nephrol       Date:  2009-12       Impact factor: 8.237

5.  Baseline characteristics of a multiethnic lupus cohort: PROFILE.

Authors:  G S Alarcón; G McGwin; M Petri; J D Reveille; R Ramsey-Goldman; R P Kimberly
Journal:  Lupus       Date:  2002       Impact factor: 2.911

6.  Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995.

Authors:  M M Ward
Journal:  Arch Intern Med       Date:  2000-11-13

7.  Outcomes in biopsy-proven lupus nephritis: evaluation of 190 white patients from a single center.

Authors:  Antoni Sisó; Manuel Ramos-Casals; Albert Bové; Pilar Brito-Zerón; Natalia Soria; Norma Nardi; Adriana Testi; Marta Perez-de-Lis; Cándido Díaz-Lagares; Alejandro Darnell; Juan Sentís; Antonio Coca
Journal:  Medicine (Baltimore)       Date:  2010-09       Impact factor: 1.889

8.  Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans.

Authors:  Bessie A Young; Charles Maynard; Edward J Boyko
Journal:  Diabetes Care       Date:  2003-08       Impact factor: 19.112

9.  Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.

Authors:  Ricard Cervera; Munther A Khamashta; Josep Font; Gian Domenico Sebastiani; Antonio Gil; Paz Lavilla; Juan Carlos Mejía; A Olcay Aydintug; Hanna Chwalinska-Sadowska; Enrique de Ramón; Antonio Fernández-Nebro; Mauro Galeazzi; Merete Valen; Alessandro Mathieu; Frédéric Houssiau; Natividad Caro; Paula Alba; Manuel Ramos-Casals; Miguel Ingelmo; Graham R V Hughes
Journal:  Medicine (Baltimore)       Date:  2003-09       Impact factor: 1.889

10.  Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study.

Authors:  A Elisabeth Hak; Elizabeth W Karlson; Diane Feskanich; Meir J Stampfer; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2009-10-15
View more
  19 in total

1.  Race/Ethnicity and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus.

Authors:  Medha Barbhaiya; Candace H Feldman; Hongshu Guan; Jose A Gómez-Puerta; Michael A Fischer; Daniel H Solomon; Brendan Everett; Karen H Costenbader
Journal:  Arthritis Rheumatol       Date:  2017-08-13       Impact factor: 10.995

2.  Initial disease severity, cardiovascular events and all-cause mortality among patients with systemic lupus erythematosus.

Authors:  Daniel Li; Kazuki Yoshida; Candace H Feldman; Cameron Speyer; Medha Barbhaiya; Hongshu Guan; Daniel H Solomon; Brendan M Everett; Karen H Costenbader
Journal:  Rheumatology (Oxford)       Date:  2020-03-01       Impact factor: 7.580

Review 3.  Lupus Nephritis: A Different Disease in European Patients?

Authors:  Vladimir Tesar; Zdenka Hruskova
Journal:  Kidney Dis (Basel)       Date:  2015-08-28

Review 4.  CKD and ESRD in US Hispanics.

Authors:  Nisa Desai; Claudia M Lora; James P Lash; Ana C Ricardo
Journal:  Am J Kidney Dis       Date:  2018-04-13       Impact factor: 8.860

Review 5.  The global burden of SLE: prevalence, health disparities and socioeconomic impact.

Authors:  Erin E Carter; Susan G Barr; Ann E Clarke
Journal:  Nat Rev Rheumatol       Date:  2016-08-25       Impact factor: 20.543

Review 6.  Cardiovascular Implications of Immune Disorders in Women.

Authors:  Caitlin A Moran; Lauren F Collins; Nour Beydoun; Puja K Mehta; Yetunde Fatade; Ijeoma Isiadinso; Tené T Lewis; Brittany Weber; Jill Goldstein; Igho Ofotokun; Arshed Quyyumi; May Y Choi; Kehmia Titanji; Cecile D Lahiri
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 23.213

7.  Sex Differences in Health Care Utilization, End-Stage Renal Disease, and Mortality Among Medicaid Beneficiaries With Incident Lupus Nephritis.

Authors:  Candace H Feldman; Anna Broder; Hongshu Guan; Jinoos Yazdany; Karen H Costenbader
Journal:  Arthritis Rheumatol       Date:  2018-02-06       Impact factor: 10.995

8.  Racial/ethnic variation in stroke rates and risks among patients with systemic lupus erythematosus.

Authors:  Medha Barbhaiya; Candace H Feldman; Hongshu Guan; Sarah K Chen; Michael A Fischer; Daniel H Solomon; Brendan M Everett; Karen H Costenbader
Journal:  Semin Arthritis Rheum       Date:  2018-07-31       Impact factor: 5.532

Review 9.  Development of a Set of Lupus-Specific, Ambulatory Care-Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study.

Authors:  Candace H Feldman; Cameron Speyer; Rachel Ashby; Bonnie L Bermas; Shamik Bhattacharyya; Eliza Chakravarty; Brendan Everett; Elizabeth Ferucci; Aimee O Hersh; Francisco M Marty; Joseph F Merola; Rosalind Ramsey-Goldman; Brad H Rovin; Mary Beth Son; Laura Tarter; Sushrut Waikar; Jinoos Yazdany; Joel S Weissman; Karen H Costenbader
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-01       Impact factor: 4.794

10.  Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications.

Authors:  May Y Choi; Daniel Li; Candace H Feldman; Kazuki Yoshida; Hongshu Guan; Seoyoung C Kim; Brendan M Everett; Karen H Costenbader
Journal:  Rheumatology (Oxford)       Date:  2021-08-02       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.